Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Enteropathy-associated T-cell lymphoma: A population-based cohort study on incidence, treatment, and outcome in the Netherlands
Published in: EJHaem
Access to document
10.1002/jha2.1049
document
INTRODUCTION: Enteropathy-associated T-cell lymphoma (EATL) is a peripheral T-cell lymphoma (PTCL) with a poor prognosis. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide consolidated by autologous stem cell transplantation (ASCT) are recommended for fit PTCL patients. The role of etoposide and ASCT in EATL is unclear. METHODS: This study reports the incidence, treatment, and outcome of EATL patients using the Netherlands Cancer Registry, with nationwide coverage of >95%. RESULTS: All patients diagnosed in 1989-2021 (n = 351, 77% treated) were identified (median age 67 years, 56%...
Frederik O Meeuwes, Mirian Brink, Wouter J Plattel, Joost S P Vermaat, Marie José Kersten, Mariëlle Wondergem, Otto Visser, Marjolein W M van der Poel, Rimke Oostvogels, F J Sherida H Woei-A-Jin, Lara Böhmer, Tjeerd J F Snijders, Gerwin A Huls, Marcel Nijland
Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
Published in: Journal of Cancer Survivorship
Access to document
10.1007/s11764-024-01694-0
document
Purpose: Studies looking into the concordance between late effects reported by physicians vs. those reported by Hodgkin lymphoma (HL) survivors are missing. Methods: A Life Situation Questionnaire focusing on late effects collected data from 1230 HL survivors (median follow-up 14.3 years). Twenty-six disease- and treatment-related late effects from various organ systems were matched with physician-recorded data. The concordance between physicians and survivors was systematically evaluated using percentage agreement and kappa statistics. Potential non-responder biases and associations with patient and disease characteristics were also investigated. Results: Agreement levels (indicated by...
Sidsel J. Juul, Sára Rossetti, Berthe M.P. Aleman, Flora E. van Leeuwen, Marleen A.E. van der Kaaij, Francesco Giusti, Paul Meijnders, John M.M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Daphne Krzisch, Camille Bigenwald, Aspasia Stamatoullas, Marc André, Wouter J. Plattel, Martin Hutchings, Maja V. Maraldo
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry
Published in: -
Access to document
10.1182/bloodadvances.2023012531
document
Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes in R/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK+) and ALK-negative (ALK-) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK+ ALCL, and ALK- ALCL (≥18 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The...
Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Reply to T. Vassilakopoulos et al
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.24.00143
document
Massimo Federico, Wouter Plattel, Martin Hutchings, Yana Stepanishyna, Catherine Fortpied, Marc André
Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
Published in: Journal of Cancer Survivorship
Access to document
10.1007/s11764-022-01305-w
document
Purpose: Little is known about the employment situation of long-term Hodgkin lymphoma (HL) survivors despite their young age at diagnosis and the favorable prognosis of the disease. In this cross-sectional study, we aim to describe the employment situation in a cohort of long-term HL survivors compared to the general population and investigate the associations with disease characteristics and treatment exposure. Methods: HL survivors > 25 years (n = 1961) were matched 1:25 to controls (n = 49,025) from the European Union Labour Force Survey. Individual treatment information was obtained...
Sidsel J. Juul, Sára Rossetti, Michal Kicinski, Marleen A.E. van der Kaaij, Francesco Giusti, Paul Meijnders, Berthe M.P. Aleman, John M.M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Marc André, Fabien Le Bras, Wouter J. Plattel, Michel Henry-Amar, Martin Hutchings, Maja V. Maraldo